Zobrazeno 1 - 10
of 198
pro vyhledávání: '"Boe Sandahl Sorensen"'
Autor:
Sara Bønløkke, Torben Steiniche, Boe Sandahl Sorensen, Gitte‐Bettina Nyvang, Jacob Christian Lindegaard, Jan Blaakær, Jesper Bertelsen, Katrine Fuglsang, Mikael Lenz Strube, Suzan Lenz, Magnus Stougaard
Publikováno v:
Molecular Oncology, Vol 18, Iss 5, Pp 1231-1244 (2024)
For cervical cancer (CC), circulating cell‐free HPV DNA (ccfHPV) may establish disease severity. Furthermore, HPV integration has been correlated to viral load and survival. In this study, pre‐treatment plasma from 139 CC cases (50 primary surger
Externí odkaz:
https://doaj.org/article/ff0349f899b14681a67f3aa4b23c11ad
Autor:
Christoffer Trier Maansson, Louise Skov Thomsen, Laura Stokkebro, Julie Gabe Dissing, Maiken Parm Ulhoi, Anders Lade Nielsen, Peter Meldgaard, Boe Sandahl Sorensen
Publikováno v:
The Journal of Liquid Biopsy, Vol 4, Iss , Pp 100141- (2024)
Introduction: Recent studies have demonstrated differences between the fragment length profiles of cell-free DNA (cfDNA) from cancer patients and healthy individuals. This has led to the development of in vitro size-selection procedures which can iso
Externí odkaz:
https://doaj.org/article/1e96b62e142f40ce9bc46948207c757a
Publikováno v:
Cancer Treatment and Research Communications, Vol 39, Iss , Pp 100802- (2024)
Background: Reliable biomarkers are needed to identify tumor recurrence of non-small cell lung cancer (NSCLC) patients after chemoradiotherapy (CRT) with curative intent. This could improve consolidation therapy of progressing patients. However, the
Externí odkaz:
https://doaj.org/article/3df6c84844b845c8b2c5af5bcd5540bc
Autor:
Christoffer Trier Maansson, Peter Meldgaard, Magnus Stougaard, Anders Lade Nielsen, Boe Sandahl Sorensen
Publikováno v:
Molecular Oncology, Vol 17, Iss 5, Pp 722-736 (2023)
Cell‐free DNA (cfDNA) in blood plasma can be bound to nucleosomes that contain post‐translational modifications representing the epigenetic profile of the cell of origin. This includes histone H3 lysine 36 trimethylation (H3K36me3), a marker of a
Externí odkaz:
https://doaj.org/article/d4898b4fdb484ec09ae806f348de054c
Autor:
Christoffer Trier Maansson, Emma Roger Andersen, Maiken Parm Ulhoi, Peter Meldgaard, Boe Sandahl Sorensen
Publikováno v:
BMC Bioinformatics, Vol 24, Iss 1, Pp 1-12 (2023)
Abstract Background EML4-ALK gene fusions are oncogenic drivers in non-small cell lung cancer (NSCLC), and liquid biopsies containing EML4-ALK fragments can be used to study tumor dynamics using next-generation sequencing (NGS). However, the sensitiv
Externí odkaz:
https://doaj.org/article/cc429b21f99f4197bc0eaf3a0f475651
Autor:
Christoffer Trier Månsson, Johan Vad‐Nielsen, Peter Meldgaard, Anders Lade Nielsen, Boe Sandahl Sorensen
Publikováno v:
Molecular Oncology, Vol 15, Iss 11, Pp 2868-2876 (2021)
Determination of tumour‐specific transcription based on liquid biopsies possesses a large diagnostic and prognostic potential in non‐small cell lung cancer (NSCLC). Cell‐free DNA (cfDNA) packed in nucleosomes mirrors the histone modification pr
Externí odkaz:
https://doaj.org/article/215d9d2d9c6e4358ba4b2f9354903872
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 3, Pp 1323-1327 (2021)
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effusions
Externí odkaz:
https://doaj.org/article/eaabbf6bfe18449eb5367df6e94ada0f
Autor:
Stine Karlsen Oversoe, Michelle Simone Clement, Britta Weber, Henning Grønbæk, Stephen Jacques Hamilton-Dutoit, Boe Sandahl Sorensen, Jens Kelsen
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background and aims Studies suggest that mutations in the CTNNB1 gene are predictive of response to immunotherapy, an emerging therapy for advanced hepatocellular carcinoma (HCC). Analysis of circulating tumor DNA (ctDNA) offers the possibil
Externí odkaz:
https://doaj.org/article/d55854123f184e32a815ea076f23f8ec
Publikováno v:
EBioMedicine, Vol 49, Iss , Pp 284-290 (2019)
Background: Numerous studies have shown that cell-free DNA (cfDNA) levels may serve as a non-invasive biomarker of a broad spectrum of acute and chronic pathologies. However, in order to make clinical decisions based on cfDNA measurements, it is esse
Externí odkaz:
https://doaj.org/article/9426b61909b04628aad5f225c53004e7
Autor:
Kristine Raaby Gammelgaard, Johan Vad-Nielsen, Michelle Simone Clement, Simone Weiss, Tina Fuglsang Daugaard, Frederik Dagnæs-Hansen, Peter Meldgaard, Boe Sandahl Sorensen, Anders Lade Nielsen
Publikováno v:
Translational Oncology, Vol 12, Iss 3, Pp 432-440 (2019)
Non-small cell lung carcinoma patients with epidermal growth factor receptor (EGFR) mutations are offered EGFR tyrosine kinase inhibitors (TKI) as first line treatment, but 20–40% of these patients do not respond. High expression of alternative rec
Externí odkaz:
https://doaj.org/article/95de9a5034e840a880f923bc69715d00